Journal
ANTIBIOTICS-BASEL
Volume 9, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/antibiotics9080500
Keywords
fosfomycin; pharmacodynamic; synergic; synergism; synergistic; infection; multidrug resistant
Categories
Ask authors/readers for more resources
Fosfomycin is being increasingly prescribed for multidrug-resistant bacterial infections. In patients with systemic involvement, intravenous fosfomycin is usually administered as a partner drug, as part of an antibiotic regimen. Hence, the knowledge of fosfomycin pharmacodynamic interactions (synergistic, additive, indifferent and antagonistic effect) is fundamental for a proper clinical management of severe bacterial infections. We performed a systematic review to point out fosfomycin's synergistic properties, when administered with other antibiotics, in order to help clinicians to maximize drug efficacy optimizing its use in clinical practice. Interactions were more frequently additive or indifferent (65.4%). Synergism accounted for 33.7% of total interactions, while antagonism occurred sporadically (0.9%). Clinically significant synergistic interactions were mostly distributed in combination with penicillins (51%), carbapenems (43%), chloramphenicol (39%) and cephalosporins (33%) in Enterobactaerales; with linezolid (74%), tetracyclines (72%) and daptomycin (56%) inStaphylococcus aureus; with chloramphenicol (53%), aminoglycosides (43%) and cephalosporins (36%) againstPseudomonas aeruginosa; with daptomycin (97%) inEnterococcusspp. and with sulbactam (75%) and penicillins (60%) and inAcinetobacterspp. fosfomycin-based antibiotic associations benefit from increase in the bactericidal effect and prevention of antimicrobial resistances. Taken together, the presence of synergistic interactions and the nearly total absence of antagonisms, make fosfomycin a good partner drug in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available